BioVie CEO buys 15,210 shares at $2.08 each

Rhea-AI Filing Summary

BIOVIE INC. (BIVI) reported that President & CEO Cuong V. Do purchased common stock on August 27, 2026. He bought 15,210 shares of BioVie common stock in open market transactions at a weighted average price of $2.08 per share, with trade prices ranging from $2.05 to $2.10. Following this purchase, he directly holds 16,117 common shares of BioVie.

Insider Trade Summary

Net Buyer: 15,210 shares

Net Buy 1 txn

Insider DO CUONG V

Role President & CEO

Bought 15,210 shs ($32K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	15,210	$2.08	$32K

Holdings After Transaction: Common Stock — 16,117 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price at which shares were purchased in several open market transactions on August 27, 2026, at prices ranging from $2.05 to $2.10, inclusive. The reporting person undertakes to provide BioVie Inc., any stockholder of BioVie Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares purchased: 15,210 shares Weighted average purchase price: $2.08 per share Price range of purchases: $2.05 to $2.10 per share +2 more

5 metrics

Shares purchased 15,210 shares Common Stock purchased on August 27, 2026

Weighted average purchase price $2.08 per share Open market purchases on August 27, 2026

Price range of purchases $2.05 to $2.10 per share Open market transactions on August 27, 2026

Shares owned after transaction 16,117 shares Direct holdings of common stock following the purchase

Net buy shares 15,210 shares Net of all reported transactions in this Form 4

Key Terms

Form 4, weighted average price, open market transactions

3 terms

Form 4 regulatory

"reported that President & CEO Cuong V. Do purchased"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market transactions financial

"shares were purchased in several open market transactions"

Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BIVI report for President & CEO Cuong V. Do?

BioVie reported that President & CEO Cuong V. Do bought 15,210 shares of common stock on August 27, 2026, in open market transactions at a weighted average price of $2.08 per share, with prices between $2.05 and $2.10. He now directly holds 16,117 shares.

At what price did the BIVI CEO buy shares in the latest Form 4?

Cuong V. Do purchased BioVie (BIVI) shares at a weighted average price of $2.08 per share. The trades on August 27, 2026 occurred in multiple open market transactions at prices ranging from $2.05 to $2.10 per share.

How many BIVI shares does the CEO hold after the reported purchase?

After the reported transaction, President & CEO Cuong V. Do directly holds 16,117 shares of BioVie common stock. This total includes the 15,210 shares he bought in open market transactions on August 27, 2026.

Was the recent BIVI insider trade a purchase or a sale?

The recent insider trade reported for BioVie (BIVI) by President & CEO Cuong V. Do was a purchase of common stock, not a sale. He acquired 15,210 shares in open market transactions on August 27, 2026.

Did the BIVI Form 4 indicate use of a Rule 10b5-1 trading plan?

No. The Form 4 for BioVie (BIVI) shows the Rule 10b5-1 checkbox as not selected, and the footnote describes the August 27, 2026 trades only as open market transactions within a price range of $2.05 to $2.10 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 08:58 PM EDT Accepted by SEC EDGAR 08/28/2026 - 08:57 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DO CUONG V

(Last) (First) (Middle)

C/O BIOVIE INC.

680 W NYE LANE STE 201

(Street)

CARSON CITY NEVADA 89703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOVIE INC. [ BIVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2026		P		15,210	A	$2.08(1)	16,117	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price at which shares were purchased in several open market transactions on August 27, 2026, at prices ranging from $2.05 to $2.10, inclusive. The reporting person undertakes to provide BioVie Inc., any stockholder of BioVie Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Cuong V Do	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)